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Background. Visceral leishmaniasis (VL) has been targeted by the World Health Organization (WHO) and 5 countries in the 
Indian subcontinent for elimination as a public health problem. To achieve this target, the WHO has developed guidelines consisting 
of 4 phases of different levels of interventions, based on vector control through indoor residual spraying of insecticide (IRS) and 
active case detection (ACD). Mathematical transmission models of VL are increasingly used for planning and assessing the efficacy 
of interventions and evaluating the intensity and timescale required to achieve the elimination target.
Methods. This paper draws together the key policy-relevant conclusions from recent transmission modeling of VL, and presents 
new predictions for VL incidence under the interventions recommended by the WHO using the latest transmission models.
Results. The model predictions suggest that the current WHO guidelines should be sufficient to reach the elimination target 
in areas that had medium VL endemicities (up to 5 VL cases per 10 000 population per year) prior to the start of interventions. 
However, additional interventions, such as extending the WHO attack phase (intensive IRS and ACD), may be required to bring for-
ward elimination in regions with high precontrol endemicities, depending on the relative infectiousness of different disease stages.
Conclusions. The potential hurdle that asymptomatic and, in particular, post-kala-azar dermal leishmaniasis cases may pose to 
reaching and sustaining the target needs to be addressed. As VL incidence decreases, the pool of immunologically naive individuals 
will grow, creating the potential for new outbreaks.
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Visceral leishmaniasis (VL), also known as kala-azar, is a 
neglected tropical disease caused by protozoan Leishmania 
parasites transmitted by female Phlebotomine sandflies. Only a 
small proportion of infected individuals develop clinical symp-
toms, which include prolonged fever and an enlarged liver and 
spleen. VL is generally considered fatal if left untreated [1, 2]. 
After recovery and, more rarely, after asymptomatic infection, 
individuals can develop post-kala-azar dermal leishmaniasis 
(PKDL), a skin rash involving macular, papular, or nodular 
lesions [3]. Individuals with PKDL are thought to contribute to 
transmission [3–6]. The largest burden of VL has traditionally 
been in the Indian subcontinent (ISC), where transmission is 
considered solely anthroponotic. In 2014 and 2015, however, 
with conflicts in East Africa, the African region reported more 
cases than the ISC [7]. The decrease in cases in the ISC has been 
attributed to Nepal, India, and Bangladesh instituting a program 
in 2005 to eliminate VL as a public health problem by 2017 [7, 8]. 
In 2014, Bhutan and Thailand joined the commitment and the 
target was set for 2020 [9]. The elimination target is annual 
incidence of <1 VL case per 10 000 inhabitants for 3 consecu-
tive years at subdistrict/district level (depending on the country) 
[2]. The program has 4 phases: a precontrol “preparatory” phase; 
a 5-year attack phase designed to bring the incidence below 1 
per 10 000 per year by 2017; a consolidation phase where inci-
dence is kept below the target for 3  years; and a maintenance 
phase to ensure sustainable reductions in incidence beyond 2020 
[10]. These phases entail different levels of intervention activ-
ities including active case detection (ACD) and vector control 
through indoor residual spraying of insecticide (IRS) or other 
effective vector control measures, which are further explained in 
the World Health Organization (WHO) guidelines [10].
Mathematical transmission models are increasingly used 
for planning and assessing the efficacy of interventions for VL, 
although challenges remain due to key biological uncertainties 
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in its transmission dynamics [11–14]. This article draws 
together the key policy-relevant conclusions from recent trans-
mission modeling of VL, and presents new predictions of the 
impact of the interventions in each WHO phase on VL inci-
dence. We also explore alternative durations of these phases, to 
aid prioritization of resources for VL control in the ISC.
OVERVIEW OF RECENT VL MODELING AND KEY 
POLICY-RELEVANT OUTCOMES
There are several published models of VL transmission dynam-
ics [11, 12]. Those which are focused on the ISC have been par-
ticularly influenced by the work of Stauch et al [15, 16]. More 
recently, modeling groups from Erasmus MC and Warwick 
University have been performing transmission modeling and 
quantitative analyses in this area [17–19], and we use these 
models in this article. We first describe the models and high-
light the main uncertainties in VL transmission dynamics.
Description of Transmission Models and Key Knowledge Gaps in VL 
Dynamics
Figure 1 illustrates the basic structure of the Erasmus MC (E0, E1) 
and Warwick models (W0, W1), with the main differences between 
models explained in the legend. The models are deterministic, and 
were parameterized using different data, but have both undergone 
geographical cross-validation against data on >5000 VL cases from 
8 endemic districts in Bihar collected by CARE India [20] (see [19] 
for full model descriptions and sensitivity analyses).
Attempts to model VL transmission and control have high-
lighted the importance of certain parameters that are highly var-
iable or remain largely unknown [12, 13, 21]. These parameters 
can be distinguished according to whether they relate to human 
aspects of infection, sandfly bionomics, or intervention efficacy. 
Regarding the human aspects of infection, the key unknown 
parameters are the duration of asymptomatic infection, the 
proportion of asymptomatic individuals who develop clinical 
symptoms, the relative infectiousness of asymptomatic individ-
uals, VL cases, and PKDL cases, and the duration of acquired 
immunity. Therefore, the models make different assumptions 
about these aspects of the natural history.
The Erasmus MC models [18, 19] consist of a set of age-struc-
tured model variants based on different assumptions about 
where the main reservoir of infection lies; namely, solely in 
symptomatic individuals (VL and PKDL; model E0), or mainly 
in asymptomatic individuals (model E1). Other variants, with 
Figure 1. Schematic presentation of the structures of model E1 and the related models E0, W1, and W0. Model W1 is similar to model E1, but has one combined compart-
ment for asymptomatic individuals (yellow), and 1 combined compartment for recovered individuals (green), and no post-kala-azar dermal leishmaniasis (PKDL; purple). For 
models E1 and W1, asymptomatic individuals (yellow compartments) are the main contributors to transmission. Models E0 and W0 have the same structures as models E1 
and W1, respectively, but asymptomatic individuals do not contribute to transmission. All 4 models have different durations of infection stages from fitting to data, which are 
listed elsewhere [19]. Indoor residual spraying reduces the populations of the sandfly compartments, and active case detection leads to a shorter duration of the symptomatic 
untreated state (dark red) in all models.
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the main reservoir of infection in previously immune individu-
als in whom infection reactivates or PKDL cases, have also been 
explored [18]. The models were parameterized with age-struc-
tured data on approximately 21 000 individuals included in the 
KalaNet bednet trial in India and Nepal [22].
In the original Warwick model (model W1) [19], asymp-
tomatic individuals constitute the main reservoir of infection, 
and PKDL cases are not included in the transmission dynam-
ics. Certain parameters, such as the durations of asymptomatic 
infection and immunity, are based on estimates from mode-
ling of the natural history of VL, using annual serological test 
and skin test results from a detailed epidemiological study in a 
high-endemicity setting in Bangladesh [17, 23]. Here, we intro-
duce 1 new model variant (model W0), which is comparable to 
model W1 except that only symptomatic individuals contribute 
to transmission, as in model E0.
Using these models, and other statistical approaches, 
attempts have been made to estimate the average durations 
of asymptomatic infection and immunity. Le Rutte et  al [19] 
reported that asymptomatic infection (defined by polymerase 
chain reaction positivity without symptoms) lasts approxi-
mately 10 months (95% confidence interval [CI], 8–14 months) 
based on the KalaNet data. Chapman et  al [17] concluded 
that the asymptomatic stage (defined by rK39 enzyme-linked 
immunosorbent assay positivity and leishmanin skin test neg-
ativity without symptoms) lasts approximately 5 months (95% 
CI, 4–5.5 months), based on the Bangladesh data. The percent-
age of asymptomatic individuals that develop VL was estimated 
by Le Rutte et al at approximately 1.5% [19], whereas Chapman 
et  al estimated it at approximately 15% [17]. These estimates 
may reflect potentially realistic possibilities at both ends of the 
spectrum [21, 24], and mainly differ because the models had 
different structures and were fitted to datasets from settings 
with different endemicities and diagnostics [19, 24].
As there are no definitive data on the duration of immunity to 
VL after (asymptomatic and symptomatic) infection, in a recent 
model comparison study [19] it was assumed to last 2 years (by 
Erasmus MC), based on fitting of the models to the KalaNet and 
CARE data [18, 19], and 5 years (by Warwick) based on previ-
ous modeling of the natural history of VL [17]. However, the 
potential implications of some individuals developing lifelong 
immunity to disease remain to be explored.
The relative infectiousness of individuals in different infec-
tion states remains under debate [13]. Despite limited data and 
reliance on strong underlying assumptions, the modelers esti-
mated the infectiousness of asymptomatics from case incidence 
data as about 2.5% that of symptomatic cases [19]. In models 
E0 and E1, PKDL cases are assumed to be half as infectious to 
sandflies as active VL cases, which is considered conservative 
based on available data [25]. Furthermore, we note that all 3 
lesion types contain detectable parasite loads [26], and have 
been shown to transmit to sandflies in historical and recent 
xenodiagnosis studies [5, 6]. Ongoing xenodiagnosis studies 
will provide more direct evidence of the relative infectiousness 
of asymptomatic individuals and PKDL cases [6, 27]. Detailed 
longitudinal follow-up studies are required to provide further 
insight into the progression of asymptomatic individuals to 
clinical disease and the duration of immunity.
Also, little is known about the bionomics of Phlebotomus argen-
tipes sandflies. All 4 models assume the same parameter values for 
sandfly bionomics [19]. Models E0 and E1 treat exposure to sand-
flies as age-dependent to explain observed age patterns in sero-
prevalence and VL incidence [18, 19]. The relationship between 
sandfly and host densities, prevalences of infected and infectious 
flies, host biting preferences, time and location of transmission, 
and P. argentipes life expectancy remain largely uncertain [12, 13]. 
Policy-Relevant Insights From Recent VL Modeling 
Modeling has shown that reducing time to diagnosis, and sub-
sequent treatment, can lead to a dramatic reduction in inci-
dence of VL cases [19, 28]. The impact of early identification 
and treatment of VL cases, for example, during fever before 
the onset of VL-specific symptoms, was explored by Medley 
et al in a model that assumes that clinical VL cases are signif-
icantly more infectious than asymptomatic or preclinical cases 
[28]. The results highlighted the importance of the timeliness 
of diagnosis, suggesting that a diagnostic capable of targeting 
earlier treatment need only be 30% sensitive to have a signif-
icant impact. However, such a diagnostic would need to be 
highly specific to justify VL treatment using current drugs. In 
this regard, it has been shown that individuals with high initial 
antibody levels, and those who seroconvert to high antibody 
levels, are more likely to develop clinical VL than individuals 
who are seronegative, or who do not seroconvert between tests 
[17, 24]. However, the specificity of using high-titer seropositiv-
ity or seroconversion to identify progressors to VL is low [24].
The impact of IRS was first studied in a model in which 
asymptomatic individuals are the main drivers of transmission 
[15]. This suggested that a large reduction in sandfly density via 
IRS (of around 60%–70%) is needed to achieve elimination. Le 
Rutte et al later demonstrated that reducing cases below 1 per 
10 000 per year could be feasible with optimal IRS (63% con-
tinuous reduction in sandfly density) in low-endemicity and 
medium-endemicity settings (≤10 cases per 10 000 per year at 
baseline). In higher-endemicity areas, additional interventions 
were advised [18]. All models assume constant effectiveness of 
IRS, which requires that susceptibility to insecticides is mon-
itored and managed, in terms of switching between different 
insecticides if resistance arises [29].
Recent modeling suggests that if asymptomatic individu-
als are the main contributors to transmission (models E1 and 
W1), the continuation of combined IRS and ACD at current 
levels (60% IRS coverage and 40-day average onset-to-treat-
ment time) should be sufficient to reach the elimination target 
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by 2020 for subdistricts with a precontrol endemicity ≤10 per 
10 000 per year [19]. However, if transmission is caused solely 
by symptomatic individuals (model E0), the models suggest 
the target will be reached years later, due to transmission 
being maintained by a remaining pool of VL and PKDL cases 
with long infectious periods. The Erasmus MC and Warwick 
models gave discrepant results on whether increasing IRS 
coverage from 60% to 80% or halving the average onset-to-
treatment time from 40 to 20  days reduced incidence more 
rapidly. These discrepancies are largely due to different esti-
mated IRS efficacies and parameterization of asymptomatic 
infection (relative infectivities and durations), and inclusion 
of PKDL (in terms of the long-term predictions). All mod-
els agreed that a combination of increasing IRS coverage and 
reducing onset-to-treatment times would lead to the target 
being reached most quickly, and that these 2 interventions 
together would be sufficient to achieve the elimination target 
in all settings.
IMPACT OF THE DIFFERENT PHASES OF THE WHO 
GUIDELINES ON VL INCIDENCE
With the 4 transmission models (models E0, E1, W0, and 
W1) we predict the effect that the different WHO phases have 
on VL incidence over time for subdistricts with high (10 per 
10 000 per year), medium (5 per 10 000 per year), and low (2 
per 10 000 per year) precontrol endemicity levels. During the 
precontrol phase without IRS and ACD, an average “onset-
to-treatment” (OT) time of 60  days is assumed [20, 30]. 
In the attack phase, active case detection is assumed to reduce 
the OT to 45  days, combined with 100% IRS coverage as 
Figure 2. Visceral leishmaniasis (VL) incidence during the World Health Organization precontrol phase (<year 0), attack phase (years 0–5), and consolidation phase (year 
5 onward) for 3 different precontrol endemicity levels (2, 5, and 10 cases per 10 000 people per year), as predicted from 4 transmission models. Oscillations are due to the 
seasonal pattern in incidence caused by seasonal variation in the sandfly population.
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mentioned in the guidelines. We interpret this 100% to be 
comparable to the maximum IRS coverage so far achieved 
in Bihar, which is equivalent to 67% of all households being 
sprayed (53% households fully sprayed and 29% partially 
sprayed [53% + 29% / 2 = 67%]) [31]. The “limited IRS” in the 
consolidation phase [10] is interpreted here as two-thirds of 
the IRS coverage in the attack phase, combined with “intensi-
fied ACD” leading to a shorter OT of 30 days.
Figure 2 shows that the attack phase brings down the incidence 
quickly, which is then sustained by the consolidation phase. If the 
IRS efficacy is relatively low (models W0 and W1), reducing the 
IRS coverage after 5 years does not appear to have a big impact 
on incidence, as incidence decreases to very low levels in most 
settings after 5 years of ACD and intensive IRS. Only model E0 
in the highly endemic precontrol setting (10 per 10 000 per year) 
suggests that the target will not be reached within 10 years with 
the current strategy. We also explored alternative durations of the 
attack phase for the 3 precontrol endemicity levels, as presented 
in Figure 3A for model E0 (see Supplementary Figure 1 for out-
comes for the other models). Increasing the duration of the attack 
phase in high precontrol endemicity settings from 5 to 10 years 
brings forward the elimination target by at least 5 years for this 
model (E0), but less so for the other models and endemicity levels 
(see Supplementary Figure 1). Doing this for a medium-endemic-
ity setting gives hardly any additional benefit in the short term 
and does not result in reaching the target earlier. In contrast, for 
low-endemicity settings, all models predict that leaving out the 
attack phase entirely, and starting with the consolidation phase, at 
worst leads to a minor increase in time to elimination. Adjusting 
the length of the attack phase to the precontrol endemicity level 
may therefore lead to more effective use of limited resources.
The distribution of the different disease states of model E0 
over time is presented in Figure 3B, which emphasizes the large 
susceptible population (blue) that accumulates when nearing 
and sustaining elimination, posing a risk factor for (re-)intro-
duction and recrudescence of infection.
ROLE OF PKDL IN MAINTAINING TRANSMISSION
The potential role of PKDL in maintaining transmission 
as VL incidence decreases is illustrated by Figure  4, which 
shows the change in the contribution of different disease 
states to transmission during the WHO phases for models E0 
and E1. The relative contribution of PKDL increases as the 
elimination target is approached. After 5 years of the attack 
phase, about 70% (model E0) or 25% (model E1) of the 
infection pressure to sandflies comes from PKDL cases. Both 
models show that the role of PKDL increases when nearing 
elimination [4, 13]. Active detection and treatment of PKDL 
cases would thus be a promising additional tool to speed up 
and sustain elimination, but diagnosis of PKDL remains a 
challenge [32, 33].
DISCUSSION
Our models suggest that the 4-phase intervention strategy, as 
described in the current WHO guidelines, is likely to be suf-
ficient to reach the target of elimination as a public health 
Figure 3. A, Predictions from model E0 for the default duration (5 years) and 2 
alternative durations (10 years and 0 years) of the attack phase for a setting with 
a high precontrol endemicity (10 cases per 10 000 people per year). Supplementary 
Figure  1 includes these predictions from all 4 models for 3 different precontrol 
endemicity settings. B, Stacked line chart of the distribution of infection states over 
time for model E0, in a setting with a high precontrol endemicity (10 cases per 
10 000 people per year) with the default 5-year attack phase starting in year 0, 
followed by the consolidation phase. Supplementary Figure 2 includes the distri-
bution of infection states over time for all 4 models in a high-endemicity setting. 
Abbreviations: PKDL, post-kala-azar dermal leishmaniasis; VL, visceral leishmania-
sis; WHO, World Health Organization.
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problem in areas that had low to medium VL endemicities (≤5 
cases per 10 000 people per year) prior to the start of interven-
tions. For higher precontrol endemicities, an extended attack 
phase (intensive IRS and ACD) may be required. Maintaining 
the target level of incidence might require the same level of 
interventions that was required to achieve it. Whether IRS or 
reducing onset-to-treatment time is the more effective inter-
vention depends on the relative infectiousness of asymptomatic 
and symptomatic individuals and the efficacy of IRS, both still 
important gaps in knowledge. If most asymptomatic individuals 
are infectious to sandflies (even if only 1/80th as infectious as 
symptomatic individuals [19]) and their duration of infection 
is as long and their rate of developing VL as low as estimated, 
then they will act as the main source of transmission. In this 
case, increasing IRS coverage will cause a greater reduction in 
transmission than reducing delays to treatment, provided IRS 
is effective in killing sandflies [15]. However, if asymptomatic 
individuals are not infectious to sandflies, or only a very small 
proportion of them are, so that clinical cases drive transmission, 
then reducing delays to treatment will lead to a greater decrease 
in incidence [28]. These varying assumptions, some of which 
are covered by the different submodels, influence the time taken 
to reach elimination.
In the model outputs, the decrease in VL incidence is solely 
attributable to the impact of interventions. However, the impact 
of the main interventions on VL incidence, or, in the case of 
IRS, even on vectorial capacity, varies significantly between 
studies [34–37]. Reported VL incidence in the Indian subconti-
nent has declined considerably since 2011, from approximately 
37 000 cases to just 6500 in 2016 [38]. The decline is likely 
multifactorial; some have attributed it to improved vector con-
trol and others to reductions in delays to treatment [39, 40]. 
However, other factors that should be borne in mind include a 
possible natural cycle of VL in the community and the effect of 
herd immunity [1, 41], alongside a decrease in risk factors for 
developing the disease, such as malnutrition.
The models reveal the potential hurdle that asymptomatic 
individuals and, in particular, PKDL cases may pose to reaching 
and sustaining the target, which is currently not addressed in 
the elimination target or general strategy. As already suggested 
by the WHO [10], we recommend including PKDL cases in 
the VL elimination strategy and target, for which a combined 
detection strategy, for example together with leprosy, may offer 
an efficient and sustainable solution. Adding PKDL in the elim-
ination target, however, requires some empirical threshold that 
has not yet been established [10].
Current models have proven to be useful tools for evaluating 
broad-scale trends in VL incidence under different assumptions 
about the underlying biology. As incidence falls, the influence of 
stochastic effects will increase, so a stochastic individual-based 
model will be required to predict the probability of true elim-
ination or resurgence in the maintenance phase, and will be 
included in future studies. When incidence decreases further, 
different (largely unknown) aspects of the transmission become 
increasingly important, such as the highly focal nature of the 
disease, the constant migration of individuals, and potential 
“super-spreading” of infection by human immunodeficiency 
virus–coinfected patients [42]. Alternative, sustainable vector 
control interventions, which are available now, and new tools 
such as a vaccine against VL or PKDL, which might become 
Figure 4. Relative contribution of different disease states to visceral leishmaniasis (VL) transmission over time during the World Health Organization–recommended inter-
ventions. In model E0 (left), only symptomatic individuals (VL and post-kala-azar dermal leishmaniasis [PKDL]) contribute to transmission. In model E1 (right), asymptomatic 
individuals are the main contributors to transmission. Both graphs are for a 10 per 10 000 persons per year precontrol endemicity setting with 5-year attack phase followed by 
the consolidation phase. Assumptions: 2.5% of treated VL cases develop PKDL, PKDL lasts for 5 years on average, and PKDL cases are half as infectious as active VL cases. 
Supplementary Figure 3 includes the relative contribution of different disease states for all 4 models.
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available in the future, could help to reduce incidence and sus-
tain the target of elimination as a public health problem. The 
potential impact of different types of vaccines is currently being 
explored by the Erasmus team.
CONCLUSIONS
Modeling analyses suggest that the current WHO strategic guid-
ance seems adequate to reach the target of elimination of VL as a 
public health problem in areas that had medium precontrol ende-
micities (up to 5 per 10 000 per year) before active case detection 
and high-coverage IRS began, but that additional interventions 
may be required in areas with higher precontrol endemicities, 
such as a longer duration of the attack phase. Asymptomatic 
individuals and PKDL cases pose a potential threat to reaching 
and sustaining elimination, leading to ongoing “hidden” trans-
mission for several years after reaching the target. This needs 
to be addressed in the elimination target and strategy. Also, the 
increasing pool of susceptible individuals that forms as VL inci-
dence decreases may be a source of new epidemics.
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